nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfamethoxazole—UGT1A9—Mycophenolic acid—psoriasis	0.191	0.244	CbGbCtD
Sulfamethoxazole—UGT1A9—Mycophenolate mofetil—psoriasis	0.107	0.136	CbGbCtD
Sulfamethoxazole—ALB—Acitretin—psoriasis	0.0707	0.0903	CbGbCtD
Sulfamethoxazole—CYP2C8—Tazarotene—psoriasis	0.0692	0.0883	CbGbCtD
Sulfamethoxazole—ALB—Mycophenolate mofetil—psoriasis	0.0331	0.0423	CbGbCtD
Sulfamethoxazole—CYP2C8—Cholecalciferol—psoriasis	0.0295	0.0377	CbGbCtD
Sulfamethoxazole—ALB—Prednisone—psoriasis	0.0265	0.0338	CbGbCtD
Sulfamethoxazole—CYP2C8—Mycophenolate mofetil—psoriasis	0.0256	0.0327	CbGbCtD
Sulfamethoxazole—CYP3A4—Calcitriol—psoriasis	0.0232	0.0297	CbGbCtD
Sulfamethoxazole—CYP2C9—Cholecalciferol—psoriasis	0.0206	0.0263	CbGbCtD
Sulfamethoxazole—CYP2C8—Hydrocortisone—psoriasis	0.0205	0.0262	CbGbCtD
Sulfamethoxazole—CYP2C8—Cyclosporine—psoriasis	0.0194	0.0248	CbGbCtD
Sulfamethoxazole—CYP3A4—Methoxsalen—psoriasis	0.0181	0.0231	CbGbCtD
Sulfamethoxazole—CYP2C9—Cyclosporine—psoriasis	0.0135	0.0173	CbGbCtD
Sulfamethoxazole—ALB—Methotrexate—psoriasis	0.0133	0.017	CbGbCtD
Sulfamethoxazole—CYP2C8—Dexamethasone—psoriasis	0.0128	0.0163	CbGbCtD
Sulfamethoxazole—CYP3A4—Cholecalciferol—psoriasis	0.012	0.0153	CbGbCtD
Sulfamethoxazole—CYP3A4—Triamcinolone—psoriasis	0.0104	0.0133	CbGbCtD
Sulfamethoxazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.0104	0.0133	CbGbCtD
Sulfamethoxazole—CYP2C9—Dexamethasone—psoriasis	0.00891	0.0114	CbGbCtD
Sulfamethoxazole—CYP3A4—Betamethasone—psoriasis	0.00891	0.0114	CbGbCtD
Sulfamethoxazole—CYP3A4—Prednisolone—psoriasis	0.00879	0.0112	CbGbCtD
Sulfamethoxazole—CYP3A4—Hydrocortisone—psoriasis	0.00833	0.0106	CbGbCtD
Sulfamethoxazole—CYP3A4—Prednisone—psoriasis	0.0083	0.0106	CbGbCtD
Sulfamethoxazole—CYP3A4—Cyclosporine—psoriasis	0.00787	0.01	CbGbCtD
Sulfamethoxazole—CYP3A4—Dexamethasone—psoriasis	0.00518	0.00661	CbGbCtD
Sulfamethoxazole—NAT1—Biological oxidations—CYP2S1—psoriasis	0.00153	0.0961	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00105	0.066	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000853	0.0537	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00065	0.0409	CbGpPWpGaD
Sulfamethoxazole—NAT2—Biological oxidations—CYP2S1—psoriasis	0.000634	0.0399	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metapathway biotransformation—CYP2S1—psoriasis	0.000625	0.0393	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000529	0.0333	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000349	0.0219	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000339	0.0213	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—NDUFA5—psoriasis	0.000307	0.0193	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00027	0.017	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000266	0.0168	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—CYP2S1—psoriasis	0.000261	0.0164	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.00025	0.0157	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000246	0.0155	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000221	0.0139	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00022	0.0138	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000219	0.0138	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000218	0.0137	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000217	0.0136	CbGpPWpGaD
Sulfamethoxazole—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.00019	0.0119	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.00018	0.0113	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000178	0.0112	CbGpPWpGaD
Sulfamethoxazole—Pancytopenia—Methotrexate—psoriasis	0.000167	0.000832	CcSEcCtD
Sulfamethoxazole—Vertigo—Triamcinolone—psoriasis	0.000167	0.000831	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000167	0.00083	CcSEcCtD
Sulfamethoxazole—Connective tissue disorder—Prednisone—psoriasis	0.000166	0.000825	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000165	0.000821	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Prednisolone—psoriasis	0.000165	0.00082	CcSEcCtD
Sulfamethoxazole—Neutropenia—Methotrexate—psoriasis	0.000165	0.000819	CcSEcCtD
Sulfamethoxazole—Insomnia—Cyclosporine—psoriasis	0.000164	0.000815	CcSEcCtD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000163	0.0102	CbGpPWpGaD
Sulfamethoxazole—Cough—Triamcinolone—psoriasis	0.000162	0.000807	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Cyclosporine—psoriasis	0.000161	0.000804	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000161	0.000801	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Hydrocortisone—psoriasis	0.000161	0.000801	CcSEcCtD
Sulfamethoxazole—Convulsion—Triamcinolone—psoriasis	0.000161	0.000801	CcSEcCtD
Sulfamethoxazole—Photosensitivity reaction—Methotrexate—psoriasis	0.000161	0.0008	CcSEcCtD
Sulfamethoxazole—Asthenia—Mycophenolic acid—psoriasis	0.000161	0.0008	CcSEcCtD
Sulfamethoxazole—Insomnia—Mycophenolate mofetil—psoriasis	0.00016	0.000795	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Cyclosporine—psoriasis	0.000159	0.000794	CcSEcCtD
Sulfamethoxazole—Nausea—Hydroxyurea—psoriasis	0.000159	0.00079	CcSEcCtD
Sulfamethoxazole—Pruritus—Mycophenolic acid—psoriasis	0.000158	0.000788	CcSEcCtD
Sulfamethoxazole—Myalgia—Triamcinolone—psoriasis	0.000158	0.000787	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Hydrocortisone—psoriasis	0.000158	0.000786	CcSEcCtD
Sulfamethoxazole—Pneumonia—Methotrexate—psoriasis	0.000158	0.000786	CcSEcCtD
Sulfamethoxazole—Eye disorder—Prednisone—psoriasis	0.000158	0.000784	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000157	0.000784	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Cyclosporine—psoriasis	0.000157	0.000784	CcSEcCtD
Sulfamethoxazole—Infestation—Methotrexate—psoriasis	0.000157	0.000781	CcSEcCtD
Sulfamethoxazole—Infestation NOS—Methotrexate—psoriasis	0.000157	0.000781	CcSEcCtD
Sulfamethoxazole—Depression—Methotrexate—psoriasis	0.000156	0.000779	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000156	0.000778	CcSEcCtD
Sulfamethoxazole—Skin disorder—Hydrocortisone—psoriasis	0.000156	0.000778	CcSEcCtD
Sulfamethoxazole—Fatigue—Cyclosporine—psoriasis	0.000156	0.000777	CcSEcCtD
Sulfamethoxazole—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000156	0.000775	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000155	0.000774	CcSEcCtD
Sulfamethoxazole—Renal failure—Methotrexate—psoriasis	0.000154	0.000768	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000154	0.00969	CbGpPWpGaD
Sulfamethoxazole—Angioedema—Dexamethasone—psoriasis	0.000154	0.000766	CcSEcCtD
Sulfamethoxazole—Angioedema—Betamethasone—psoriasis	0.000154	0.000766	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000154	0.000765	CcSEcCtD
Sulfamethoxazole—Anorexia—Hydrocortisone—psoriasis	0.000153	0.000764	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Mycophenolic acid—psoriasis	0.000153	0.000763	CcSEcCtD
Sulfamethoxazole—Stomatitis—Methotrexate—psoriasis	0.000153	0.000761	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000153	0.000759	CcSEcCtD
Sulfamethoxazole—Immune system disorder—Prednisone—psoriasis	0.000152	0.000758	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Triamcinolone—psoriasis	0.000152	0.000754	CcSEcCtD
Sulfamethoxazole—Vertigo—Dexamethasone—psoriasis	0.000151	0.000754	CcSEcCtD
Sulfamethoxazole—Vertigo—Betamethasone—psoriasis	0.000151	0.000754	CcSEcCtD
Sulfamethoxazole—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000151	0.00949	CbGpPWpGaD
Sulfamethoxazole—Insomnia—Prednisolone—psoriasis	0.000149	0.000742	CcSEcCtD
Sulfamethoxazole—Hepatobiliary disease—Methotrexate—psoriasis	0.000148	0.000739	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Cyclosporine—psoriasis	0.000148	0.000737	CcSEcCtD
Sulfamethoxazole—Dizziness—Mycophenolic acid—psoriasis	0.000148	0.000737	CcSEcCtD
Sulfamethoxazole—Mental disorder—Prednisone—psoriasis	0.000148	0.000735	CcSEcCtD
Sulfamethoxazole—Malnutrition—Prednisone—psoriasis	0.000147	0.00073	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000147	0.00073	CcSEcCtD
Sulfamethoxazole—Agranulocytosis—Methotrexate—psoriasis	0.000146	0.000729	CcSEcCtD
Sulfamethoxazole—Convulsion—Betamethasone—psoriasis	0.000146	0.000727	CcSEcCtD
Sulfamethoxazole—Convulsion—Dexamethasone—psoriasis	0.000146	0.000727	CcSEcCtD
Sulfamethoxazole—Insomnia—Hydrocortisone—psoriasis	0.000146	0.000725	CcSEcCtD
Sulfamethoxazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000145	0.00911	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000144	0.000719	CcSEcCtD
Sulfamethoxazole—Urticaria—Cyclosporine—psoriasis	0.000144	0.000716	CcSEcCtD
Sulfamethoxazole—Myalgia—Dexamethasone—psoriasis	0.000143	0.000714	CcSEcCtD
Sulfamethoxazole—Myalgia—Betamethasone—psoriasis	0.000143	0.000714	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Cyclosporine—psoriasis	0.000143	0.000713	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Cyclosporine—psoriasis	0.000143	0.000713	CcSEcCtD
Sulfamethoxazole—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000143	0.00899	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Mycophenolic acid—psoriasis	0.000142	0.000709	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Hydrocortisone—psoriasis	0.000142	0.000705	CcSEcCtD
Sulfamethoxazole—Rash—Mycophenolic acid—psoriasis	0.000141	0.000703	CcSEcCtD
Sulfamethoxazole—Dermatitis—Mycophenolic acid—psoriasis	0.000141	0.000702	CcSEcCtD
Sulfamethoxazole—Hepatitis—Methotrexate—psoriasis	0.000141	0.000701	CcSEcCtD
Sulfamethoxazole—Urticaria—Mycophenolate mofetil—psoriasis	0.00014	0.000699	CcSEcCtD
Sulfamethoxazole—Headache—Mycophenolic acid—psoriasis	0.00014	0.000698	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Hydrocortisone—psoriasis	0.00014	0.000697	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00014	0.000695	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Mycophenolate mofetil—psoriasis	0.00014	0.000695	CcSEcCtD
Sulfamethoxazole—Urinary tract disorder—Methotrexate—psoriasis	0.000139	0.000693	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000139	0.000692	CcSEcCtD
Sulfamethoxazole—Fatigue—Hydrocortisone—psoriasis	0.000139	0.000691	CcSEcCtD
Sulfamethoxazole—Urethral disorder—Methotrexate—psoriasis	0.000138	0.000687	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000138	0.000687	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Dexamethasone—psoriasis	0.000137	0.000685	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Betamethasone—psoriasis	0.000137	0.000685	CcSEcCtD
Sulfamethoxazole—Insomnia—Triamcinolone—psoriasis	0.000137	0.000682	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Triamcinolone—psoriasis	0.000135	0.000673	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Dexamethasone—psoriasis	0.000135	0.000671	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Betamethasone—psoriasis	0.000135	0.000671	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Betamethasone—psoriasis	0.000135	0.00067	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Dexamethasone—psoriasis	0.000135	0.00067	CcSEcCtD
Sulfamethoxazole—Angioedema—Prednisone—psoriasis	0.000134	0.000667	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Cyclosporine—psoriasis	0.000133	0.000664	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Triamcinolone—psoriasis	0.000133	0.000664	CcSEcCtD
Sulfamethoxazole—Erythema multiforme—Methotrexate—psoriasis	0.000133	0.000663	CcSEcCtD
Sulfamethoxazole—Nausea—Mycophenolic acid—psoriasis	0.000133	0.000662	CcSEcCtD
Sulfamethoxazole—Vertigo—Prednisone—psoriasis	0.000132	0.000656	CcSEcCtD
Sulfamethoxazole—Eye disorder—Methotrexate—psoriasis	0.000132	0.000655	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000132	0.000655	CcSEcCtD
Sulfamethoxazole—Tinnitus—Methotrexate—psoriasis	0.000131	0.000654	CcSEcCtD
Sulfamethoxazole—Anorexia—Dexamethasone—psoriasis	0.000131	0.000653	CcSEcCtD
Sulfamethoxazole—Anorexia—Betamethasone—psoriasis	0.000131	0.000653	CcSEcCtD
Sulfamethoxazole—Urticaria—Prednisolone—psoriasis	0.000131	0.000652	CcSEcCtD
Sulfamethoxazole—Fatigue—Triamcinolone—psoriasis	0.000131	0.00065	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00013	0.000648	CcSEcCtD
Sulfamethoxazole—Asthenia—Cyclosporine—psoriasis	0.00013	0.000647	CcSEcCtD
Sulfamethoxazole—Pruritus—Cyclosporine—psoriasis	0.000128	0.000638	CcSEcCtD
Sulfamethoxazole—Urticaria—Hydrocortisone—psoriasis	0.000128	0.000637	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—NDUFA5—psoriasis	0.000128	0.00802	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—CARM1—psoriasis	0.000128	0.00802	CbGpPWpGaD
Sulfamethoxazole—Immune system disorder—Methotrexate—psoriasis	0.000127	0.000633	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Hydrocortisone—psoriasis	0.000127	0.000633	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Hydrocortisone—psoriasis	0.000127	0.000633	CcSEcCtD
Sulfamethoxazole—Convulsion—Prednisone—psoriasis	0.000127	0.000633	CcSEcCtD
Sulfamethoxazole—Mediastinal disorder—Methotrexate—psoriasis	0.000127	0.000632	CcSEcCtD
Sulfamethoxazole—Asthenia—Mycophenolate mofetil—psoriasis	0.000127	0.000631	CcSEcCtD
Sulfamethoxazole—Chills—Methotrexate—psoriasis	0.000126	0.000629	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000125	0.000624	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000125	0.000624	CcSEcCtD
Sulfamethoxazole—Pruritus—Mycophenolate mofetil—psoriasis	0.000125	0.000622	CcSEcCtD
Sulfamethoxazole—Myalgia—Prednisone—psoriasis	0.000125	0.000622	CcSEcCtD
Sulfamethoxazole—Arthralgia—Prednisone—psoriasis	0.000125	0.000622	CcSEcCtD
Sulfamethoxazole—Insomnia—Betamethasone—psoriasis	0.000124	0.000619	CcSEcCtD
Sulfamethoxazole—Insomnia—Dexamethasone—psoriasis	0.000124	0.000619	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000124	0.000618	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Cyclosporine—psoriasis	0.000124	0.000617	CcSEcCtD
Sulfamethoxazole—Mental disorder—Methotrexate—psoriasis	0.000123	0.000614	CcSEcCtD
Sulfamethoxazole—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000123	0.00773	CbGpPWpGaD
Sulfamethoxazole—Malnutrition—Methotrexate—psoriasis	0.000123	0.00061	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Prednisolone—psoriasis	0.000121	0.000604	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Betamethasone—psoriasis	0.000121	0.000603	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Dexamethasone—psoriasis	0.000121	0.000603	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000121	0.000602	CcSEcCtD
Sulfamethoxazole—Urticaria—Triamcinolone—psoriasis	0.00012	0.000599	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Triamcinolone—psoriasis	0.00012	0.000596	CcSEcCtD
Sulfamethoxazole—Dizziness—Cyclosporine—psoriasis	0.00012	0.000596	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Prednisone—psoriasis	0.00012	0.000596	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Betamethasone—psoriasis	0.00012	0.000595	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Dexamethasone—psoriasis	0.00012	0.000595	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000119	0.000591	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Betamethasone—psoriasis	0.000119	0.000591	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Hydrocortisone—psoriasis	0.000119	0.00059	CcSEcCtD
Sulfamethoxazole—Fatigue—Dexamethasone—psoriasis	0.000119	0.00059	CcSEcCtD
Sulfamethoxazole—Fatigue—Betamethasone—psoriasis	0.000119	0.00059	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Prednisone—psoriasis	0.000117	0.000585	CcSEcCtD
Sulfamethoxazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000117	0.00739	CbGpPWpGaD
Sulfamethoxazole—Dizziness—Mycophenolate mofetil—psoriasis	0.000117	0.000582	CcSEcCtD
Sulfamethoxazole—Skin disorder—Prednisone—psoriasis	0.000116	0.000579	CcSEcCtD
Sulfamethoxazole—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000116	0.00731	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000116	0.00729	CbGpPWpGaD
Sulfamethoxazole—Asthenia—Hydrocortisone—psoriasis	0.000115	0.000575	CcSEcCtD
Sulfamethoxazole—Vomiting—Cyclosporine—psoriasis	0.000115	0.000573	CcSEcCtD
Sulfamethoxazole—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000115	0.00721	CbGpPWpGaD
Sulfamethoxazole—Rash—Cyclosporine—psoriasis	0.000114	0.000568	CcSEcCtD
Sulfamethoxazole—Anorexia—Prednisone—psoriasis	0.000114	0.000568	CcSEcCtD
Sulfamethoxazole—Dermatitis—Cyclosporine—psoriasis	0.000114	0.000568	CcSEcCtD
Sulfamethoxazole—Pruritus—Hydrocortisone—psoriasis	0.000114	0.000567	CcSEcCtD
Sulfamethoxazole—Headache—Cyclosporine—psoriasis	0.000113	0.000565	CcSEcCtD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000113	0.00712	CbGpPWpGaD
Sulfamethoxazole—Gastrointestinal pain—Betamethasone—psoriasis	0.000112	0.00056	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Dexamethasone—psoriasis	0.000112	0.00056	CcSEcCtD
Sulfamethoxazole—Vomiting—Mycophenolate mofetil—psoriasis	0.000112	0.000559	CcSEcCtD
Sulfamethoxazole—Hypersensitivity—Triamcinolone—psoriasis	0.000112	0.000556	CcSEcCtD
Sulfamethoxazole—Rash—Mycophenolate mofetil—psoriasis	0.000111	0.000555	CcSEcCtD
Sulfamethoxazole—Dermatitis—Mycophenolate mofetil—psoriasis	0.000111	0.000554	CcSEcCtD
Sulfamethoxazole—Headache—Mycophenolate mofetil—psoriasis	0.000111	0.000551	CcSEcCtD
Sulfamethoxazole—Vertigo—Methotrexate—psoriasis	0.00011	0.000548	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Hydrocortisone—psoriasis	0.00011	0.000548	CcSEcCtD
Sulfamethoxazole—Leukopenia—Methotrexate—psoriasis	0.00011	0.000546	CcSEcCtD
Sulfamethoxazole—Urticaria—Dexamethasone—psoriasis	0.000109	0.000544	CcSEcCtD
Sulfamethoxazole—Urticaria—Betamethasone—psoriasis	0.000109	0.000544	CcSEcCtD
Sulfamethoxazole—Musculoskeletal discomfort—Prednisone—psoriasis	0.000109	0.000543	CcSEcCtD
Sulfamethoxazole—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000109	0.00686	CbGpPWpGaD
Sulfamethoxazole—Dizziness—Prednisolone—psoriasis	0.000109	0.000543	CcSEcCtD
Sulfamethoxazole—Asthenia—Triamcinolone—psoriasis	0.000109	0.000541	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Betamethasone—psoriasis	0.000109	0.000541	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Dexamethasone—psoriasis	0.000109	0.000541	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Dexamethasone—psoriasis	0.000109	0.000541	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Betamethasone—psoriasis	0.000109	0.000541	CcSEcCtD
Sulfamethoxazole—NAT2—Metabolism—CYP2S1—psoriasis	0.000108	0.00682	CbGpPWpGaD
Sulfamethoxazole—Insomnia—Prednisone—psoriasis	0.000108	0.000539	CcSEcCtD
Sulfamethoxazole—Nausea—Cyclosporine—psoriasis	0.000108	0.000536	CcSEcCtD
Sulfamethoxazole—Pruritus—Triamcinolone—psoriasis	0.000107	0.000534	CcSEcCtD
Sulfamethoxazole—Cough—Methotrexate—psoriasis	0.000107	0.000533	CcSEcCtD
Sulfamethoxazole—Dizziness—Hydrocortisone—psoriasis	0.000106	0.00053	CcSEcCtD
Sulfamethoxazole—Convulsion—Methotrexate—psoriasis	0.000106	0.000529	CcSEcCtD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000106	0.00665	CbGpPWpGaD
Sulfamethoxazole—Dyspepsia—Prednisone—psoriasis	0.000105	0.000525	CcSEcCtD
Sulfamethoxazole—Nausea—Mycophenolate mofetil—psoriasis	0.000105	0.000522	CcSEcCtD
Sulfamethoxazole—Arthralgia—Methotrexate—psoriasis	0.000104	0.00052	CcSEcCtD
Sulfamethoxazole—Myalgia—Methotrexate—psoriasis	0.000104	0.00052	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Prednisone—psoriasis	0.000104	0.000518	CcSEcCtD
Sulfamethoxazole—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000104	0.00654	CbGpPWpGaD
Sulfamethoxazole—Rash—Prednisolone—psoriasis	0.000104	0.000517	CcSEcCtD
Sulfamethoxazole—Dermatitis—Prednisolone—psoriasis	0.000104	0.000517	CcSEcCtD
Sulfamethoxazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000104	0.000516	CcSEcCtD
Sulfamethoxazole—Fatigue—Prednisone—psoriasis	0.000103	0.000514	CcSEcCtD
Sulfamethoxazole—Headache—Prednisolone—psoriasis	0.000103	0.000514	CcSEcCtD
Sulfamethoxazole—Vomiting—Hydrocortisone—psoriasis	0.000102	0.000509	CcSEcCtD
Sulfamethoxazole—Rash—Hydrocortisone—psoriasis	0.000101	0.000505	CcSEcCtD
Sulfamethoxazole—Dermatitis—Hydrocortisone—psoriasis	0.000101	0.000505	CcSEcCtD
Sulfamethoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000101	0.00635	CbGpPWpGaD
Sulfamethoxazole—Headache—Hydrocortisone—psoriasis	0.000101	0.000502	CcSEcCtD
Sulfamethoxazole—Dizziness—Triamcinolone—psoriasis	0.0001	0.000499	CcSEcCtD
Sulfamethoxazole—Anaphylactic shock—Methotrexate—psoriasis	0.0001	0.000498	CcSEcCtD
Sulfamethoxazole—Asthenia—Dexamethasone—psoriasis	9.87e-05	0.000491	CcSEcCtD
Sulfamethoxazole—Asthenia—Betamethasone—psoriasis	9.87e-05	0.000491	CcSEcCtD
Sulfamethoxazole—Nervous system disorder—Methotrexate—psoriasis	9.81e-05	0.000489	CcSEcCtD
Sulfamethoxazole—Thrombocytopenia—Methotrexate—psoriasis	9.8e-05	0.000488	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Prednisone—psoriasis	9.79e-05	0.000488	CcSEcCtD
Sulfamethoxazole—Nausea—Prednisolone—psoriasis	9.79e-05	0.000487	CcSEcCtD
Sulfamethoxazole—Pruritus—Betamethasone—psoriasis	9.73e-05	0.000484	CcSEcCtD
Sulfamethoxazole—Pruritus—Dexamethasone—psoriasis	9.73e-05	0.000484	CcSEcCtD
Sulfamethoxazole—Skin disorder—Methotrexate—psoriasis	9.72e-05	0.000484	CcSEcCtD
Sulfamethoxazole—Vomiting—Triamcinolone—psoriasis	9.64e-05	0.00048	CcSEcCtD
Sulfamethoxazole—Nausea—Hydrocortisone—psoriasis	9.56e-05	0.000476	CcSEcCtD
Sulfamethoxazole—Rash—Triamcinolone—psoriasis	9.55e-05	0.000476	CcSEcCtD
Sulfamethoxazole—Dermatitis—Triamcinolone—psoriasis	9.55e-05	0.000475	CcSEcCtD
Sulfamethoxazole—Anorexia—Methotrexate—psoriasis	9.54e-05	0.000475	CcSEcCtD
Sulfamethoxazole—Urticaria—Prednisone—psoriasis	9.51e-05	0.000474	CcSEcCtD
Sulfamethoxazole—Headache—Triamcinolone—psoriasis	9.49e-05	0.000473	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Prednisone—psoriasis	9.47e-05	0.000471	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Prednisone—psoriasis	9.47e-05	0.000471	CcSEcCtD
Sulfamethoxazole—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.46e-05	0.00595	CbGpPWpGaD
Sulfamethoxazole—Diarrhoea—Betamethasone—psoriasis	9.41e-05	0.000468	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Dexamethasone—psoriasis	9.41e-05	0.000468	CcSEcCtD
Sulfamethoxazole—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.33e-05	0.00587	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	9.24e-05	0.00581	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	9.14e-05	0.00575	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	9.13e-05	0.00574	CbGpPWpGaD
Sulfamethoxazole—Musculoskeletal discomfort—Methotrexate—psoriasis	9.12e-05	0.000454	CcSEcCtD
Sulfamethoxazole—Dizziness—Betamethasone—psoriasis	9.09e-05	0.000453	CcSEcCtD
Sulfamethoxazole—Dizziness—Dexamethasone—psoriasis	9.09e-05	0.000453	CcSEcCtD
Sulfamethoxazole—Insomnia—Methotrexate—psoriasis	9.05e-05	0.000451	CcSEcCtD
Sulfamethoxazole—Nausea—Triamcinolone—psoriasis	9e-05	0.000448	CcSEcCtD
Sulfamethoxazole—Dyspnoea—Methotrexate—psoriasis	8.92e-05	0.000444	CcSEcCtD
Sulfamethoxazole—ALB—Hemostasis—SERPINB8—psoriasis	8.89e-05	0.0056	CbGpPWpGaD
Sulfamethoxazole—Hypersensitivity—Prednisone—psoriasis	8.82e-05	0.000439	CcSEcCtD
Sulfamethoxazole—Dyspepsia—Methotrexate—psoriasis	8.81e-05	0.000439	CcSEcCtD
Sulfamethoxazole—Vomiting—Betamethasone—psoriasis	8.74e-05	0.000435	CcSEcCtD
Sulfamethoxazole—Vomiting—Dexamethasone—psoriasis	8.74e-05	0.000435	CcSEcCtD
Sulfamethoxazole—Decreased appetite—Methotrexate—psoriasis	8.7e-05	0.000433	CcSEcCtD
Sulfamethoxazole—Rash—Betamethasone—psoriasis	8.67e-05	0.000432	CcSEcCtD
Sulfamethoxazole—Rash—Dexamethasone—psoriasis	8.67e-05	0.000432	CcSEcCtD
Sulfamethoxazole—Dermatitis—Betamethasone—psoriasis	8.66e-05	0.000431	CcSEcCtD
Sulfamethoxazole—Dermatitis—Dexamethasone—psoriasis	8.66e-05	0.000431	CcSEcCtD
Sulfamethoxazole—Gastrointestinal disorder—Methotrexate—psoriasis	8.64e-05	0.00043	CcSEcCtD
Sulfamethoxazole—Fatigue—Methotrexate—psoriasis	8.63e-05	0.00043	CcSEcCtD
Sulfamethoxazole—Headache—Betamethasone—psoriasis	8.61e-05	0.000429	CcSEcCtD
Sulfamethoxazole—Headache—Dexamethasone—psoriasis	8.61e-05	0.000429	CcSEcCtD
Sulfamethoxazole—Asthenia—Prednisone—psoriasis	8.59e-05	0.000428	CcSEcCtD
Sulfamethoxazole—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	8.49e-05	0.00534	CbGpPWpGaD
Sulfamethoxazole—Pruritus—Prednisone—psoriasis	8.47e-05	0.000422	CcSEcCtD
Sulfamethoxazole—Diarrhoea—Prednisone—psoriasis	8.19e-05	0.000408	CcSEcCtD
Sulfamethoxazole—Gastrointestinal pain—Methotrexate—psoriasis	8.18e-05	0.000407	CcSEcCtD
Sulfamethoxazole—Nausea—Betamethasone—psoriasis	8.17e-05	0.000407	CcSEcCtD
Sulfamethoxazole—Nausea—Dexamethasone—psoriasis	8.17e-05	0.000407	CcSEcCtD
Sulfamethoxazole—Urticaria—Methotrexate—psoriasis	7.95e-05	0.000396	CcSEcCtD
Sulfamethoxazole—Dizziness—Prednisone—psoriasis	7.92e-05	0.000394	CcSEcCtD
Sulfamethoxazole—Abdominal pain—Methotrexate—psoriasis	7.91e-05	0.000394	CcSEcCtD
Sulfamethoxazole—Body temperature increased—Methotrexate—psoriasis	7.91e-05	0.000394	CcSEcCtD
Sulfamethoxazole—NAT1—Metabolism—CAT—psoriasis	7.84e-05	0.00494	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Prednisone—psoriasis	7.61e-05	0.000379	CcSEcCtD
Sulfamethoxazole—Rash—Prednisone—psoriasis	7.55e-05	0.000376	CcSEcCtD
Sulfamethoxazole—Dermatitis—Prednisone—psoriasis	7.54e-05	0.000376	CcSEcCtD
Sulfamethoxazole—Headache—Prednisone—psoriasis	7.5e-05	0.000373	CcSEcCtD
Sulfamethoxazole—ALB—Folate Metabolism—CAT—psoriasis	7.47e-05	0.0047	CbGpPWpGaD
Sulfamethoxazole—Hypersensitivity—Methotrexate—psoriasis	7.37e-05	0.000367	CcSEcCtD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	7.33e-05	0.00461	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—CRP—psoriasis	7.29e-05	0.00458	CbGpPWpGaD
Sulfamethoxazole—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	7.24e-05	0.00456	CbGpPWpGaD
Sulfamethoxazole—Asthenia—Methotrexate—psoriasis	7.18e-05	0.000357	CcSEcCtD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—APOE—psoriasis	7.13e-05	0.00449	CbGpPWpGaD
Sulfamethoxazole—Nausea—Prednisone—psoriasis	7.11e-05	0.000354	CcSEcCtD
Sulfamethoxazole—Pruritus—Methotrexate—psoriasis	7.08e-05	0.000353	CcSEcCtD
Sulfamethoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.03e-05	0.00442	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—IL4—psoriasis	6.86e-05	0.00432	CbGpPWpGaD
Sulfamethoxazole—Diarrhoea—Methotrexate—psoriasis	6.85e-05	0.000341	CcSEcCtD
Sulfamethoxazole—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.84e-05	0.0043	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	6.74e-05	0.00424	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	6.7e-05	0.00421	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.65e-05	0.00419	CbGpPWpGaD
Sulfamethoxazole—Dizziness—Methotrexate—psoriasis	6.62e-05	0.000329	CcSEcCtD
Sulfamethoxazole—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	6.41e-05	0.00404	CbGpPWpGaD
Sulfamethoxazole—Vomiting—Methotrexate—psoriasis	6.36e-05	0.000317	CcSEcCtD
Sulfamethoxazole—Rash—Methotrexate—psoriasis	6.31e-05	0.000314	CcSEcCtD
Sulfamethoxazole—Dermatitis—Methotrexate—psoriasis	6.3e-05	0.000314	CcSEcCtD
Sulfamethoxazole—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.28e-05	0.00395	CbGpPWpGaD
Sulfamethoxazole—Headache—Methotrexate—psoriasis	6.27e-05	0.000312	CcSEcCtD
Sulfamethoxazole—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.24e-05	0.00392	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.15e-05	0.00387	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—APOE—psoriasis	6.09e-05	0.00383	CbGpPWpGaD
Sulfamethoxazole—Nausea—Methotrexate—psoriasis	5.94e-05	0.000296	CcSEcCtD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—CAT—psoriasis	5.93e-05	0.00373	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—CRP—psoriasis	5.93e-05	0.00373	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—ICAM1—psoriasis	5.45e-05	0.00343	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.38e-05	0.00339	CbGpPWpGaD
Sulfamethoxazole—NAT1—Metabolism—PPARG—psoriasis	5.31e-05	0.00334	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—CARM1—psoriasis	5.3e-05	0.00333	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.13e-05	0.00323	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	5.1e-05	0.00321	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—CRP—psoriasis	4.71e-05	0.00296	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.64e-05	0.00292	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—NDUFA5—psoriasis	4.44e-05	0.00279	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	4.33e-05	0.00272	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.33e-05	0.00272	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.27e-05	0.00268	CbGpPWpGaD
Sulfamethoxazole—ALB—SLC-mediated transmembrane transport—CP—psoriasis	4.25e-05	0.00267	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	4.24e-05	0.00267	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—IFNG—psoriasis	4.15e-05	0.00261	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.14e-05	0.0026	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CYP2S1—psoriasis	3.77e-05	0.00237	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—NDUFA5—psoriasis	3.62e-05	0.00228	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—NFKB1—psoriasis	3.45e-05	0.00217	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.37e-05	0.00212	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.32e-05	0.00209	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.3e-05	0.00208	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.29e-05	0.00207	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—CAT—psoriasis	3.26e-05	0.00205	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CYP2S1—psoriasis	3.08e-05	0.00194	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.74e-05	0.00172	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet degranulation—VEGFA—psoriasis	2.68e-05	0.00169	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TNF—psoriasis	2.68e-05	0.00169	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.68e-05	0.00169	CbGpPWpGaD
Sulfamethoxazole—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.66e-05	0.00167	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—ITGAL—psoriasis	2.58e-05	0.00162	CbGpPWpGaD
Sulfamethoxazole—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.56e-05	0.00161	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—APOE—psoriasis	2.53e-05	0.00159	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—TP53—psoriasis	2.37e-05	0.00149	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—NDUFA5—psoriasis	2.34e-05	0.00147	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—NDUFA5—psoriasis	2.32e-05	0.00146	CbGpPWpGaD
Sulfamethoxazole—NAT2—Metabolism—PPARG—psoriasis	2.2e-05	0.00139	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.18e-05	0.00137	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.17e-05	0.00136	CbGpPWpGaD
Sulfamethoxazole—ALB—Folate Metabolism—IL6—psoriasis	2.17e-05	0.00136	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.16e-05	0.00136	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.13e-05	0.00134	CbGpPWpGaD
Sulfamethoxazole—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.06e-05	0.0013	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CYP2S1—psoriasis	1.99e-05	0.00125	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.98e-05	0.00124	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CYP2S1—psoriasis	1.98e-05	0.00124	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—NDUFA5—psoriasis	1.9e-05	0.0012	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CARM1—psoriasis	1.84e-05	0.00116	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.77e-05	0.00112	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.72e-05	0.00108	CbGpPWpGaD
Sulfamethoxazole—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.72e-05	0.00108	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CYP2S1—psoriasis	1.62e-05	0.00102	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.61e-05	0.00101	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CARM1—psoriasis	1.5e-05	0.000945	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.4e-05	0.000883	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—NDUFA5—psoriasis	1.25e-05	0.000789	CbGpPWpGaD
Sulfamethoxazole—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.19e-05	0.000749	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—CAT—psoriasis	1.13e-05	0.000713	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CYP2S1—psoriasis	1.07e-05	0.000671	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—NOS2—psoriasis	1.06e-05	0.000667	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	0.000655	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.04e-05	0.000651	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CARM1—psoriasis	9.7e-06	0.00061	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CARM1—psoriasis	9.65e-06	0.000607	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—CAT—psoriasis	9.24e-06	0.000581	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.07e-06	0.000571	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.02e-06	0.000567	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—APOE—psoriasis	8.81e-06	0.000554	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.47e-06	0.000533	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CARM1—psoriasis	7.9e-06	0.000497	CbGpPWpGaD
Sulfamethoxazole—UGT1A9—Metabolism—PPARG—psoriasis	7.67e-06	0.000483	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.38e-06	0.000464	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—APOE—psoriasis	7.18e-06	0.000452	CbGpPWpGaD
Sulfamethoxazole—PTGS1—Metabolism—PPARG—psoriasis	6.25e-06	0.000393	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—VEGFA—psoriasis	6.14e-06	0.000386	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—CAT—psoriasis	5.97e-06	0.000376	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—CAT—psoriasis	5.93e-06	0.000373	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CARM1—psoriasis	5.21e-06	0.000328	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—CAT—psoriasis	4.86e-06	0.000306	CbGpPWpGaD
Sulfamethoxazole—ALB—Hemostasis—TP53—psoriasis	4.64e-06	0.000292	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—APOE—psoriasis	4.64e-06	0.000292	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—APOE—psoriasis	4.61e-06	0.00029	CbGpPWpGaD
Sulfamethoxazole—CYP2C8—Metabolism—PPARG—psoriasis	4.04e-06	0.000254	CbGpPWpGaD
Sulfamethoxazole—ALB—Metabolism—PPARG—psoriasis	4.02e-06	0.000253	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—APOE—psoriasis	3.77e-06	0.000237	CbGpPWpGaD
Sulfamethoxazole—CYP2C9—Metabolism—PPARG—psoriasis	3.29e-06	0.000207	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—CAT—psoriasis	3.2e-06	0.000202	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—APOE—psoriasis	2.49e-06	0.000157	CbGpPWpGaD
Sulfamethoxazole—CYP3A4—Metabolism—PPARG—psoriasis	2.17e-06	0.000136	CbGpPWpGaD
